193 related articles for article (PubMed ID: 31571328)
1. Akt inhibition synergizes with polycomb repressive complex 2 inhibition in the treatment of multiple myeloma.
Rizk M; Rizq O; Oshima M; Nakajima-Takagi Y; Koide S; Saraya A; Isshiki Y; Chiba T; Yamazaki S; Ma A; Jin J; Iwama A; Mimura N
Cancer Sci; 2019 Dec; 110(12):3695-3707. PubMed ID: 31571328
[TBL] [Abstract][Full Text] [Related]
2. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
[No Abstract] [Full Text] [Related]
3. Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma.
Nakagawa M; Fujita S; Katsumoto T; Yamagata K; Ogawara Y; Hattori A; Kagiyama Y; Honma D; Araki K; Inoue T; Kato A; Inaki K; Wada C; Ono Y; Yamamoto M; Miura O; Nakashima Y; Kitabayashi I
Cancer Sci; 2019 Jan; 110(1):194-208. PubMed ID: 30343511
[TBL] [Abstract][Full Text] [Related]
4. [Novel epigenetic therapies for multiple myeloma].
Mimura N
Rinsho Ketsueki; 2021; 62(4):314-320. PubMed ID: 33967157
[TBL] [Abstract][Full Text] [Related]
5. Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors.
Yang X; Li F; Konze KD; Meslamani J; Ma A; Brown PJ; Zhou MM; Arrowsmith CH; Kaniskan HÜ; Vedadi M; Jin J
J Med Chem; 2016 Aug; 59(16):7617-33. PubMed ID: 27468126
[TBL] [Abstract][Full Text] [Related]
6. EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma.
Kusakabe Y; Chiba T; Oshima M; Koide S; Rizq O; Aoyama K; Ao J; Kaneko T; Kanzaki H; Kanayama K; Maeda T; Saito T; Nakagawa R; Kobayashi K; Kiyono S; Nakamura M; Ogasawara S; Suzuki E; Nakamoto S; Yasui S; Mikata R; Muroyama R; Kanda T; Maruyama H; Kato J; Mimura N; Ma A; Jin J; Zen Y; Otsuka M; Kaneda A; Iwama A; Kato N
Sci Rep; 2021 Nov; 11(1):21396. PubMed ID: 34725436
[TBL] [Abstract][Full Text] [Related]
7. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
Alzrigat M; Párraga AA; Agarwal P; Zureigat H; Österborg A; Nahi H; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2017 Feb; 8(6):10213-10224. PubMed ID: 28052011
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia.
Xu B; On DM; Ma A; Parton T; Konze KD; Pattenden SG; Allison DF; Cai L; Rockowitz S; Liu S; Liu Y; Li F; Vedadi M; Frye SV; Garcia BA; Zheng D; Jin J; Wang GG
Blood; 2015 Jan; 125(2):346-57. PubMed ID: 25395428
[TBL] [Abstract][Full Text] [Related]
9. Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.
Honma D; Kanno O; Watanabe J; Kinoshita J; Hirasawa M; Nosaka E; Shiroishi M; Takizawa T; Yasumatsu I; Horiuchi T; Nakao A; Suzuki K; Yamasaki T; Nakajima K; Hayakawa M; Yamazaki T; Yadav AS; Adachi N
Cancer Sci; 2017 Oct; 108(10):2069-2078. PubMed ID: 28741798
[TBL] [Abstract][Full Text] [Related]
10. Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition.
Mimura N; Hideshima T; Shimomura T; Suzuki R; Ohguchi H; Rizq O; Kikuchi S; Yoshida Y; Cottini F; Jakubikova J; Cirstea D; Gorgun G; Minami J; Tai YT; Richardson PG; Utsugi T; Iwama A; Anderson KC
Cancer Res; 2014 Aug; 74(16):4458-69. PubMed ID: 24934808
[TBL] [Abstract][Full Text] [Related]
11. Ezh1 and Ezh2 differentially regulate PSD-95 gene transcription in developing hippocampal neurons.
Henriquez B; Bustos FJ; Aguilar R; Becerra A; Simon F; Montecino M; van Zundert B
Mol Cell Neurosci; 2013 Nov; 57():130-43. PubMed ID: 23932971
[TBL] [Abstract][Full Text] [Related]
12. EZH2 Methyltransferase Activity Controls Pten Expression and mTOR Signaling during Fear Memory Reconsolidation.
Jarome TJ; Perez GA; Hauser RM; Hatch KM; Lubin FD
J Neurosci; 2018 Aug; 38(35):7635-7648. PubMed ID: 30030400
[TBL] [Abstract][Full Text] [Related]
13. Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells.
Zeng D; Liu M; Pan J
Oncotarget; 2017 Jan; 8(2):3396-3411. PubMed ID: 27926488
[TBL] [Abstract][Full Text] [Related]
14. EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes.
Hernando H; Gelato KA; Lesche R; Beckmann G; Koehr S; Otto S; Steigemann P; Stresemann C
Mol Cancer Ther; 2016 Feb; 15(2):287-98. PubMed ID: 26590165
[TBL] [Abstract][Full Text] [Related]
15. An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.
Konze KD; Ma A; Li F; Barsyte-Lovejoy D; Parton T; Macnevin CJ; Liu F; Gao C; Huang XP; Kuznetsova E; Rougie M; Jiang A; Pattenden SG; Norris JL; James LI; Roth BL; Brown PJ; Frye SV; Arrowsmith CH; Hahn KM; Wang GG; Vedadi M; Jin J
ACS Chem Biol; 2013; 8(6):1324-34. PubMed ID: 23614352
[TBL] [Abstract][Full Text] [Related]
16. Polycomb Repressive Complex 2 Proteins EZH1 and EZH2 Regulate Timing of Postnatal Hepatocyte Maturation and Fibrosis by Repressing Genes With Euchromatic Promoters in Mice.
Grindheim JM; Nicetto D; Donahue G; Zaret KS
Gastroenterology; 2019 May; 156(6):1834-1848. PubMed ID: 30689973
[TBL] [Abstract][Full Text] [Related]
17. Long residence time inhibition of EZH2 in activated polycomb repressive complex 2.
Van Aller GS; Pappalardi MB; Ott HM; Diaz E; Brandt M; Schwartz BJ; Miller WH; Dhanak D; McCabe MT; Verma SK; Creasy CL; Tummino PJ; Kruger RG
ACS Chem Biol; 2014 Mar; 9(3):622-9. PubMed ID: 24304166
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.
Agarwal P; Alzrigat M; Párraga AA; Enroth S; Singh U; Ungerstedt J; Österborg A; Brown PJ; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2016 Feb; 7(6):6809-23. PubMed ID: 26755663
[TBL] [Abstract][Full Text] [Related]
19. Six Years (2012-2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2-Pyridone Compounds.
Fioravanti R; Stazi G; Zwergel C; Valente S; Mai A
Chem Rec; 2018 Dec; 18(12):1818-1832. PubMed ID: 30338896
[TBL] [Abstract][Full Text] [Related]
20. The competitive mechanism of EZH1 and EZH2 in promoting oral squamous cell carcinoma.
Chen J; Tang S; Zheng Q; Li J; Jiang H; Lu H; Liao G; Li K; Liang Y
Exp Cell Res; 2024 Mar; 436(1):113957. PubMed ID: 38309675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
